S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Will Crypto Make People Rich Again Starting April, 2024? (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

$3.89
+0.07 (+1.83%)
(As of 02/23/2024 ET)
Today's Range
$3.81
$3.96
50-Day Range
$3.40
$5.01
52-Week Range
$3.19
$23.16
Volume
43,760 shs
Average Volume
78,096 shs
Market Capitalization
$86.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Acrivon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
504.1% Upside
$23.50 Price Target
Short Interest
Bearish
2.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.63) to ($2.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.62 out of 5 stars

Medical Sector

684th out of 942 stocks

Pharmaceutical Preparations Industry

311th out of 428 stocks


ACRV stock logo

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

ACRV Stock Price History

ACRV Stock News Headlines

Acrivon Therapeutics (NASDAQ:ACRV) Trading Down 4.6%
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyst Ratings for Acrivon Therapeutics
Recap: Acrivon Therapeutics Q3 Earnings
Analyst Expectations for Acrivon Therapeutics's Future
See More Headlines
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2023
Today
2/25/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$26.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+504.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-31,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.16 per share

Miscellaneous

Free Float
20,574,000
Market Cap
$86.32 million
Optionable
Not Optionable
Beta
1.24
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Peter Blume-Jensen M.D. (Age 61)
    Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
    Comp: $1.01M
  • Ms. Kristina Masson M.B.A. (Age 43)
    Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director
  • Mr. Rasmus Holm-Jorgensen (Age 53)
    Chief Financial Officer
    Comp: $1M
  • Dr. Eric J. Devroe Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $614.78k
  • Ms. Katharine Peterson CPA
    Vice President of Finance & Accounting
  • Dr. Adam D. Levy M.B.A.
    Ph.D., Senior VP and Head of Investor Relations & Corporate Affairs
  • Mr. Bruce Close
    Vice President of Quality & Compliance
  • Ms. Mary-Alice Miller J.D. (Age 50)
    Chief Legal Officer
  • Ms. Parvin Miah
    VP & Head of Human Resources
  • Dr. Erick Gamelin M.D. (Age 66)
    Ph.D., Chief Development Officer
    Comp: $480.72k














ACRV Stock Analysis - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings
or view top-rated stocks.

What is Acrivon Therapeutics' stock price target for 2024?

6 analysts have issued 12-month price targets for Acrivon Therapeutics' shares. Their ACRV share price targets range from $20.00 to $26.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 504.1% from the stock's current price.
View analysts price targets for ACRV
or view top-rated stocks among Wall Street analysts.

How have ACRV shares performed in 2024?

Acrivon Therapeutics' stock was trading at $4.92 at the beginning of the year. Since then, ACRV stock has decreased by 20.9% and is now trading at $3.89.
View the best growth stocks for 2024 here
.

When is Acrivon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our ACRV earnings forecast
.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings results on Friday, August, 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.02.

What ETF holds Acrivon Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio.

When did Acrivon Therapeutics IPO?

(ACRV) raised $100 million in an IPO on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

Who are Acrivon Therapeutics' major shareholders?

Acrivon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.14%), Northern Trust Corp (0.36%), Bridgeway Capital Management LLC (0.14%), Barclays PLC (0.11%) and Exchange Traded Concepts LLC (0.06%). Insiders that own company stock include Ltd Chione and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRV) was last updated on 2/25/2024 by MarketBeat.com Staff